Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

Oragenics (OGEN) announced the selection of Southern Star Research as its Clinical Research Organization, CRO, for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion. “Partnering with Southern Star Research ensures we are leveraging experienced, regionally specialized clinical leadership to advance ONP-002,” said Dr James Kelly, Chief Medical Officer of Oragenics. “They bring operational rigor, startup speed, and therapeutic area experience needed to move this important program forward efficiently and cost-effectively.”